Effect of endothelium mimicking self-assembled nanomatrices on cell adhesion and spreading of human endothelial cells and smooth muscle cells

The goal of this study is to develop unique native endothelium mimicking nanomatrices and evaluate their effects on adhesion and spreading of human umbilical vein endothelial cells (HUVECs) and aortic smooth muscle cells (AoSMCs). These nanomatrices were developed by self-assembly of peptide amphiphiles (PAs) through a solvent evaporation technique. Three PAs, one containing the Tyr-Ile-Gly-Ser-Arg (YIGSR) ligand, the second containing the Val-Ala-Pro-Gly (VAPG) ligand, and a third without cell adhesive ligands, were developed. Cell adhesion and spreading were evaluated by a PicoGreen-DNA assay and live/dead assay, respectively. Our results show that PA-YIGSR significantly enhances HUVEC adhesion (26,704 ± 2708), spreading (84 ± 8%), and proliferation (50 ± 2%) compared with that of other PAs. PA-VAPG and PA-YIGSR showed significantly greater AoSMC adhesion compared with that of PA-S. PA-VAPG also showed significantly greater spreading of AoSMCs (63 ± 11%) compared with that of other PAs. Also, all the PAs showed significantly reduced platelet adhesion compared with that of collagen I (control). These findings would facilitate the development of novel vascular grafts, heart valves, and cell-based therapies for cardiovascular diseases.From the Clinical EditorThe goal of this study was to develop unique native endothelium mimicking nanomatrices and evaluate their effects on adhesion and spreading of human umbilical vein endothelial cells (HUVECs) and aortic smooth muscle cells (AoSMCs). These nanomatrices were developed by self-assembly of peptide amphiphiles through a solvent evaporation technique. The findings are expected to facilitate the development of novel vascular grafts, heart valves, and cell based therapies for cardiovascular diseases.     

中西医结合治疗急性动脉栓塞过程中甲状腺激素测定的临床意义

目的：探讨甲状腺激素水平在急性动脉栓塞中中西医结合治疗过程中的变化规律及其临床意义。方法：利用放射免疫分析法对４０例本病患者及３０例健康对照组进行血清甲状腺激素测定，观察中西医结合治疗前后的变化，结果；４０例病人均存在在低Ｔ３、低Ｔ４和高ｒＴ３血症，且以重症病人最明显，Ｔ３水平低于０．５ｎｍｏｌ／Ｌ者病情危重，Ｔ４低于５０ｎｍｏｌ／Ｌ者预后不良；低Ｔ３、低Ｔ４和高ｒＴ３血症均随中西医结合有效治疗后     

健康教育防制儿童营养性贫血的可行性研究

本文以大规模随机化人群实验,用铁剂治疗、铁剂预防和空白对照的方法论证了健康教育做为儿童营养性贫血防制对策与措施的可行性.结果证实健康教育与药物治疗相比前者具有受益人群广泛、发挥作用长效、预防病种广谱、投入少效益高和人群依从性好等优点,比传统的药物治疗和预防更有推广价值,对儿童营养性贫血和类似的儿童常见病的防制是经济、有效的措施.特别是对大规模的人群实施干预只有健康教育是可行的.在预防和治疗疾病过程中也应转变唯药物有效的观念,重视心理和行为的作用,对健康教育给予应有的重视.     

Lymphoscintigraphy as a predictor of lymphatic drainage from cutaneous melanoma

Background: If cutaneous lymphoscintigraphy (CL) is accurate in predicting the draining lymph node basins at risk from primary axial melanomas, then regional metastases should only occur in those lymph node basins identified by CL. Methods: This study is a retrospective review of patients undergoing CL for primary axial melanomas from June 1, 1985, until June 31, 1992. Data retrieved included age, gender, number of basins identified, location of basins identified, management of basins, recurrence in lymphatics, development of distant disease, and long-term follow-up. Results: A total of 181 patients underwent elective LND, and 48 patients (27%) had melanoma in the nodes within the dissected basin. Of these 181 patients, seven developed nodal metastases as their site of first recurrence. All seven recurrences were seen at sites dissected or at sites indicated by CL, which the primary surgeon elected not to treat initially. Of the 116 patients observed, 16 (14%) developed lymph node metastases as their first site of recurrence. Fifteen of these 16 patients had their site of lymph node metastases predicted by CL. In this study, CL predicted 98.6% of all lymph node metastases. Conclusions: The high overall reliability of CL as demonstrated by long-term follow-up indicates that the information obtained by CL can be reliably used to guide intervention. Initial evaluation of patients with high-risk cutaneous melanomas at sites with ambiguous lymphatic drainage must include CL in order to determine the draining lymph node basins and to plan therapy. Presented at the 47th Annual Cancer Symposium of The Society of Surgical Oncology, Houston, Texas, March 17–20, 1994.